Avanir, The Michael J. Fox Foundation for Parkinson's Research neurology news

Avanir received a grant of about $570,000 from the foundation to study AVP-923 to treat Parkinson's disease (PD) levodopa-induced dyskinesia (PD-LID). Next year, Avanir will start a double-blind, placebo-controlled, North American Phase II trial to evaluate AVP-923 in about 16 patients with PD-LID. Patients will receive AVP-923 or placebo for two weeks separated by a two-week break. At the end of each treatment period, patients will receive a two-hour levodopa infusion to test AVP-923's effect on PD-LID. Avanir expects data from the trial in 1H14. AVP-923 is also in a Phase II trial to treat agitation in Alzheimer's disease (AD) (see BioCentury, Sept. 10)...